Takfa 1mg Capsule

Takfa 1mg Capsule is a medication administered after a transplant to protect the body from rejecting a new organ (heart, liver, or kidney). This class of medicine belongs to immunosuppressant as it contains active ingredient Tacrolimus. It functions by weakening the immune system so that it does not attack the new organs of the body. It should be taken in dose and duration as advice by the doctor. Don't take more than the recommended dose.​

• Prevention of organ rejection in transplant patients

Undesired symptoms or responses vary from person to person as the human body reacts differently to the Takfa 1mg Capsule, but they typically resolve naturally within a few days as the body adjusts to the medicine, requiring no medical attention. In case these symptoms don't go away and you face severe side effects, then immediately consult your doctor or medical team. Some of the common side effects of the capsule are:

• Increased glucose level in blood
• Insomnia (difficulty sleeping)
• Tremors
• Headache
• Abnormal liver function tests
• Infection
• Kidney damage
• High blood pressure

• Takfa 1mg Capsule should not be taken by anybody with a history of renal, hepatic, cardiovascular, hypoglycemia, or fluid retention. It can be taken on an empty or full stomach as prescribed by your doctor.
• It's recommended to inform your doctor before taking any other drugs because this capsule can interact with them. It is not recommended to break, crush, or chew the drug.

• Takfa 1mg Capsule is used to suppress the body's immune system. It is an immunosuppressant that helps the body accept the new organ after transplant (heart, liver, and kidney).
• It consists of tacrolimus that binds to FKBP-12, and it inhibits calcineurin and IL-2 production, and as a result, the immune response is suppressed.

• Lawrance, I. C., & COPELAND, T. S. (2008). Rectal tacrolimus in the treatment of resistant ulcerative proctitis. Alimentary pharmacology & therapeutics, 28(10), 1214-1220.
• Chisholm, M. A., & Middleton, M. D. (2006). Modified-release tacrolimus. Annals of Pharmacotherapy, 40(2), 270-275.
• Kondo, H., Abe, T., Hashimoto, H., Uchida, S., Irimajiri, S., Hara, M., & Sugawara, S. (2004). Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis: a randomized, double blind, placebo controlled dose-finding study. The Journal of Rheumatology, 31(2), 243-251.
• Badri, P., Dutta, S., Coakley, E., Cohen, D., Ding, B., Podsadecki, T. ... & Menon, R. (2015). Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. American Journal of Transplantation, 15(5), 1313-1322.
• Casson, D. H., Eltumi, M., Tomlin, S., Walker-Smith, J. A., & Murch, S. H. (2000). Topical tacrolimus may be effective in the treatment of oral and perineal Crohn's disease. Gut, 47(3), 436-440.
• Vitko, S., Wlodarczyk, Z., Kyllönen, L., Czajkowski, Z., Margreiter, R., Backman, L. ... & TERRA Study Group. (2006). Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: results of a multicenter study. American Journal of Transplantation, 6(3), 531-538.